Resilient US consumer spending and ongoing inflation keep central bank policy highly data-dependent, which keeps many investors focused on broad indices and cash. That leaves less attention on smaller companies where pricing is set more by neglect than by fundamentals. This is where the Small Cap Clinical Stage Biotechs Trading At A Discount screener can help. This article highlights three stocks that currently look especially interesting.

The three stocks below are just a starting sample from this idea. The full screen surfaced 55 more small-cap clinical-stage biotechs with equally compelling narratives that are not covered here. Head straight into the Small Cap Clinical Stage Biotechs Trading At A Discount screener to analyze, compare, and identify which discounted clinical candidates best fit your watchlist.

Oncolytics Biotech (ONCY)

Oncolytics Biotech is a clinical-stage cancer company developing pelareorep, an intravenously delivered oncolytic immunotherapy for hard-to-treat gastrointestinal tumors including metastatic colorectal, anal and pancreatic cancers, which is exactly the type of pipeline that fits the Small Cap Clinical Stage Biotechs Trading At A Discount theme. The company does not currently generate meaningful revenue, so the investment story is centered on this drug program and its clinical data. Oncolytics Biotech has a market cap of about $109 million.

Oncolytics Biotech may appeal to investors who are looking for a focused, high-risk biotech where the science and regulatory pathway may be further along than the share price suggests. Pelareorep now has three FDA Fast Track designations in GI cancers and an FDA-aligned pivotal design for the REO 033 colorectal trial. At the same time, the company is still pre-commercial with recent quarterly losses of about $9 million and less than a year of cash. Although Oncolytics Biotech is still an early-stage, pre-revenue business, recent GI cancer data and experienced deal makers on the leadership team offer a compelling story despite the risks.

That leadership team is central to the most-followed Narrative on the Simply Wall St community. The thesis is that Oncolytics Biotech is being valued primarily for its financial problems, while investors may be overlooking the potential of its lead cancer therapy, pelareorep. Early clinical data in colorectal, anal, and pancreatic cancers have been encouraging, while three FDA Fast Track designations and a clearer path towards pivotal trials could provide important catalysts.

The narrative also points to the company's new leadership team, including executives with experience in major biotech transactions, as a potential advantage in securing the funding or partnerships needed to advance the drug. Of course, risks remain present, with limited cash and possible shareholder dilution making this a highly speculative opportunity.

Edesa Biotech (EDSA)

Edesa Biotech is a clinical-stage biopharmaceutical company focused on treatments for inflammatory and immune-related diseases, with its Phase 3 monoclonal antibody EB05 for acute respiratory distress syndrome providing the clearest link to the Small Cap Clinical Stage Biotechs Trading At A Discount theme alongside earlier-stage assets like EB07 and EB01. The company currently does not report meaningful revenue, and its value is tied to the progress of this pipeline. Edesa Biotech has a market cap of about $67 million.

Edesa Biotech provides exposure to a small-cap pipeline where late-stage data could be highly consequential. The Phase 3 EB05 program in acute respiratory distress syndrome and Phase 2 EB07 for pulmonary fibrosis are being funded by recent equity raises that extend the cash runway. However, those same financings and ongoing losses of more than $11 million over the first nine months of 2026 highlight dilution and funding risk. If the encouraging exploratory paridiprubart ARDS and acute kidney injury signals reported in June 2026 are replicated in larger samples, the stock’s current discount and high volatility could be reassessed by the market. The key consideration is whether this concentrated late-stage exposure aligns with the level of risk you are prepared to accept.

Edesa Biotech’s high-stakes late-stage pipeline can look binary from the outside; yet the real story sits in the detail. Review the 5 warning signs (3 are major!) before deciding whether the recent cash raises are a lifeline or a warning sign.

Rani Therapeutics Holdings (RANI)

Rani Therapeutics Holdings is a clinical-stage biotherapeutics company developing the RaniPill, a capsule designed to deliver complex biologic drugs orally instead of by injection. This ties it directly to the Small Cap Clinical Stage Biotechs Trading At A Discount theme through programs like RT-105, RT-111 and its obesity and rare disease candidates. The company currently generates about $5 million of revenue from its biotechnology activities in the United States and has a market cap of roughly $117 million.

Rani Therapeutics provides exposure to the shift toward oral versions of injectable biologic drugs, with the RaniPill platform now supported by early human data for obesity candidate RT-114 and recent partnerships with ProGen and PegBio. The stock sits in the classic small cap biotech tension between promise and pressure, with a large patent estate, early revenue and recent board and CFO hires on one side, and ongoing losses, limited cash and reliance on external funding on the other. If you are interested in clinical-stage stories where platform validation and upcoming obesity data are potential catalysts for how the market values the pipeline, Rani is a candidate for closer review.

Rani Therapeutics is trying to turn early oral biologics and obesity buzz into something more concrete, yet the real story sits in the fine print of its analysis report for Rani Therapeutics Holdings.

Seeking Fresh Alternatives Before Others?

Fresh ideas often move first, and the strongest watchlists catch that early breakout momentum while it still flies under the radar for now. Do not delay ; get in early.

1. Spot cash-rich companies that keep compounding quietly by reviewing the list of solid balance sheets and fundamentals (50 results) before that quality premium gets fully priced in.
2. Identify potential breakout trends in gold producers with the curated 34 elite gold producer stocks and see which miners already have momentum building behind them.
3. Explore the next wave in AI infrastructure by scanning the 55 AI infrastructure stocks while these enablers of computing power are still being underfollowed.

Simply Wall St analyst Andrew Legget and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.